DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc.(“Ceragenix”) (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology today announced that the National Institutes of Health (“NIH”) has awarded a $1.66 million grant to the University of Utah to fund research evaluating a Cerashield™ coating to reduce orthopedic implant infections. Roy Bloebaum, PhD, Research Professor at the University of Utah and Career Scientist and Director, Bone and Joint Research Laboratory of the Veterans Administration Hospital, Salt Lake City, is the principal investigator on the grant. The grant will fund preclinical evaluation of orthopedic implants coated with CSA-13, the active ingredient in Cerashield™ coatings. Multiple in vitro tests have demonstrated that CSA-13 has potent activity against a broad spectrum of strains of bacteria, including multidrug resistant strains such as Methicillin Resistant Staph Aureus (MRSA), which are associated with orthopedic implant infections. Paul B. Savage, PhD, Professor at Brigham Young University and inventor of CSA-13 is a co-investigator on the grant.
